Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis

ABSTRACT

Background

Pharmacoeconomic studies comparing the cost of adalimumab biosimilars versus the originator and conventional drugs in psoriasis are lacking.

Research design and methods

To assess the cost per responder of adalimumab biosimilars versus the originator and methotrexate for psoriasis treatment. A cost per responder analysis comparing adalimumab biosimilars MSB11022 (Idacio®) and ABP 501 (Amgevita®), and methotrexate to the originator (Humira®) was performed. The incremental cost per responder was calculated by multiplying the cost of treatment based on the perspective of the National Healthcare System and number needed to treat for each therapy.

Results

Considering the PASI75 response rate at 16 weeks, the cost per responder for MSB11022 and ABP 501 compared to the originator was € 500 versus 1,831 and € 968 versus 1,949, respectively. For the same endpoint, the cost per responder for subcutaneous or oral methotrexate was € 543 or 34 compared to 2,117 for adalimumab originator. At an indirect comparison among methotrexate, MSB11022 and ABP 501, the costs per PASI75 responder at week 16 were 2%, 26%, 27% and 50% of that of the originator, respectively.

Conclusions

The use of biosimilars was confirmed as a valuable pharmacoeconomic strategy to lower healthcare cost in patients with psoriasis.

KEYWORDS:

• Psoriasis
• cost per responder
• methotrexate
• adalimumab
• biosimilar

Funding

This paper was not funded.

Declaration of interests

P Gisondi has been a consultant and/or speaker for AbbVie, Almirall, Amgen, Janssen, Leo-pharma, Eli Lilly, Novartis, Pierre Fabre, Sandoz, Sanofi and Union Chimique Belge. G Girolomoni has served as consultant and/or speaker for AbbVie, Almirall, Amgen, Biogen, Boehringer-Ingelheim, BristolMeyers Squibb, Eli-Lilly, Leo Pharma, Novartis, Pfizer, Regeneron, Samsung bioepis, Sanofi and Union Chimique Belge. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

P Gisondi and P Armeni, conceived and designed the study; P Gisondi, P Armeni, D Geat, F Bellinato and M Maurelli were involved in the analysis and interpretation of the data; all the authors contributed to drafting the paper and revising it critically for intellectual content. All the authors have read and agreed to the published version of the manuscript.

Supplemental data

Supplemental data for this article can be accessed here.

Correction Statement

This article has been corrected with minor changes. These changes do not impact the academic content of the article.